Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician. We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
Bellone
Stefania
S
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Yale University School of Medicine, New Haven, CT 06520-8063, USA.
Shah
Hemendrah R
HR
McKenney
Jesse K
JK
Stone
Pamela J B
PJ
Santin
Alessandro D
AD
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000188:drug therapy*; D009570:Nitriles / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000378:metabolism; D014057:Tomography, X-Ray Computed; D014230:Triazoles / Q000627:therapeutic use*
D047072:Aromatase Inhibitors; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D000077384:Anastrozole